Securities Code: 300692
Securities Abbreviation: Zhongfu Technology
Announcement Number: 2026-074
Anhui Zhongfu Yuanchuang Technology Group Co., Ltd. Progress Announcement on the Acquisition of Junke Zhengyuan Equity
The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
I. Overview of the Transaction
On April 27, 2026, the company disclosed the announcement titled "Announcement on the Company's Plan to Acquire Junke Zhengyuan Equity and the Proposed Signing of the Framework Agreement" (Announcement Number: 2026-066). The company's wholly-owned subsidiary, Beijing Dingfu Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Dingfu Pharmaceutical"), is planning to acquire Junke Zhengyuan (Beijing) Drug Research Co., Ltd. (hereinafter referred to as "Junke Zhengyuan") and its integrated CRO asset control (hereinafter referred to as "this transaction"). The overall estimated value of the equity to be acquired is 1 billion yuan, and upon completion of the transaction, Junke Zhengyuan will be included in the company's consolidated financial statements.